Dolby Laboratories (DLB) Stock Price & How to Invest

Dolby Laboratories licenses audio and imaging technologies to device makers, content creators, and distributors, earning royalties each time its formats are embedded in hardware or content. Its flagship brands (Dolby Atmos for immersive audio and Dolby Vision for HDR imaging) sit inside televisions, smartphones, PCs, set-top boxes, sound systems, streaming platforms, cinemas, and increasingly automotive infotainment. The model is asset-light: Dolby invests heavily in R&D and standardization, then monetizes the resulting patents and trademarks at very high gross margins once a format reaches critical mass.

The investment picture is one of a mature, profitable franchise rather than a hypergrowth name. Revenue is in the ~$1.35 billion range (both fiscal 2025 and the trailing twelve months to June 2026), with fiscal 2025 net income near $255 million and trailing net income of about $226 million, the balance sheet carries little to no debt and a large cash and investments position, and the company returns capital through a growing dividend and buybacks. Growth is tied to the pace of new-format adoption (Atmos and Vision penetration across TV, mobile, and cars), which drives mid-single-digit royalty gains, offset by lumpy licensing true-ups and consumer-electronics cyclicality that make quarter-to-quarter results uneven.

The fiscal third quarter (to June 26, 2026) showed that lumpiness: revenue of about $305 million was roughly 3% lower than a year earlier and GAAP net income was about $29 million, after a strong fiscal second quarter of about $396 million in revenue. Non-GAAP EPS of $0.69 still edged past the roughly $0.67 consensus. Since then Dolby has announced an expanded partnership with Meta that brings Dolby Atmos and Dolby Vision across Meta devices, including its AI glasses, and Formula 1 races on Apple TV are set to stream in Dolby Atmos alongside Dolby Vision. Fiscal fourth-quarter results are scheduled for November 17, 2026.

Dolby's revenue is concentrated in patent and technology licensing, so expiring patents and the need to keep introducing successful new formats are structural risks to long-term royalty streams. Results are exposed to consumer-electronics cyclicality and are lumpy because of periodic licensing true-ups and catch-up payments, which can swing quarterly comparisons meaningfully. A slowdown in TV, smartphone, or PC unit shipments would directly pressure royalties, and license renewals with major device makers can reset economics. Competition from Xperi/DTS, Sony, and other audio and imaging IP holders, plus the risk that a customer favors royalty-free or in-house alternatives, could erode share over time. Growth is modest, so multiple compression is a risk if the market expects more than mid-single-digit expansion. The June 2026 quarter, when revenue fell about 3% year over year and GAAP net income dropped to about $29 million, is a recent example of how uneven individual quarters can be.

3 analysts publish price targets on DLB, averaging $79.00 against a $59.95 price as of October 2026, or +31.8%. The published targets run from $62.00 to $90.00, a moderate spread, and the ratings split 3 buy, 1 hold, 0 sell. Over the last six months there have been 0 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full DLB forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Dolby Laboratories. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Atmos and Vision penetration. The core growth engine is broader adoption of Dolby Atmos and Dolby Vision across TVs, smartphones, PCs, and streaming content. The most optimistic published target, $90.00, assumes this works close to its best case.

The case against. Dolby's revenue is concentrated in patent and technology licensing, so expiring patents and the need to keep introducing successful new formats are structural risks to long-term royalty streams. The most pessimistic target, $62.00, is roughly what DLB is worth if this bites instead.

Read the full bull and bear case on DLB, including what would have to change to break either one. Walnut is not an investment adviser.

No. Dolby Laboratories (DLB) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Dolby Laboratories's investor relations page or your broker.

• Revenue (TTM): ~$1.35B; fiscal Q3 2026 ~$305M, down ~3% year over year
• Net income (TTM): ~$226M (FY2025 ~$255M)
• Margins (TTM): Gross ~88%, operating ~12.6%, net ~16.7%
• Fiscal Q3 2026 EPS: $0.69 non-GAAP vs ~$0.67 consensus
• FY2026 revenue: Guided ~$1.4B-$1.45B; consensus ~$1.43B
• Market cap: ~$5.7B at ~$60.38 (Oct 16, 2026)
• P/E (trailing / forward): ~26x / ~13x
• Dividend (yield): ~$1.44/yr (~2.4%)

Dolby trades at a mid-20s trailing GAAP earnings multiple that falls to about 13 times forward non-GAAP estimates (consensus near $4.58 per share for fiscal 2027). The valuation embeds a steady, high-margin licensing franchise with about $670 million of cash against minimal debt and trailing free cash flow of roughly $330 million, rather than a rapid grower. The fiscal fourth-quarter report on November 17, 2026 has a consensus near $1.20 per share on about $373 million of revenue.

If you want DLB exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to DLB: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get DLB exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (FVD), which spreads the position across many companies. Or build it into a focused thematic portfolio, so DLB sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where DLB fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

DLB is a durable, cash-rich licensing franchise with a real technology moat and modest growth, priced as a mature compounder rather than a breakout story. Fiscal 2026 has been uneven quarter to quarter, with a strong first half and a softer June quarter, while new design wins with Meta's smart glasses and Formula 1 on Apple TV extend the formats into new surfaces. The fiscal fourth-quarter report on November 17, 2026 closes out the year. Walnut is not an investment adviser.

Whether DLB is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is DLB a buy or a sell?, and where the stock could go from here in the DLB stock forecast.

For income investors, whether DLB pays a dividend and how the payout looks is covered in does DLB pay a dividend? And to weigh DLB against a peer, read the full side-by-side comparisons: DLB vs IP and DLB vs XPER.